Compare BioNTech SE - ADR (BNTX) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Western Alliance Bancorporation — how do they compare? BioNTech SE - ADR trades at $92.23 (market cap $23.31B), while Western Alliance Bancorporation trades at $81.46 (market cap $8.78B). The key difference: BioNTech SE - ADR is far larger — about 2.7× Western Alliance Bancorporation's market cap, and Western Alliance Bancorporation pays a 2.09% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | WAL | |
|---|---|---|
Market Cap | $23.31B | $8.78B |
Sector | Health | Financials |
52-Week High | $119.34 | $96.08 |
52-Week Low | $83.89 | $66.70 |
Enterprise Value | $6.60B | — |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.
Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.
Western Alliance Bancorporation (WAL) trades at $81.39, up 0.06% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals with a P/E of 9.08, net income margin of 25.43%, and consistent earnings beats in recent quarters. Recent developments include the launch of WA VenueX, a digital asset liquidity platform, and recognition as Arizona's top bank by Forbes in 2026.
Outlook remains positive with a consensus price target of $93.86, implying 15% upside, supported by 79% analyst buy ratings. Risks include negative operating cash flow and institutional selling, but revenue growth and profitability trends provide a solid foundation for investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
